Product Information
PREGABALIN 300 MG CAPSULE is a generic product labeled by Major Pharmaceuticals, priced at $0.0665 per EA under NDC 00904700504. Its NADAC has been published 367 times since Sep 25, 2019.
FDA first approved this application on Jul 19, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904700504
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA210432FDA Approved
7/19/2019
TE Code
AB
On Market Since
7/19/2019
Price Statistics
The NADAC for PREGABALIN 300 MG CAPSULE has been published 367 times since Sep 25, 2019, and over the history we have for it it has declined 70.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0665 per EA |
|---|---|
| All-time high | $0.2260 (Nov 13, 2019) |
| All-time low | $0.0628 (Nov 20, 2024) |
| 52-week high | $0.0750 |
| 52-week low | $0.0644 |
| Median price | $0.1006 |
| Average price | $0.1127 |
| Largest weekly change | +30.8% (Aug 21, 2024) |
| Weeks tracked | 367 |
| Tracking since | Sep 25, 2019 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PREGABALIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN 300 MG CAPSULE, manufactured by Major Pharmaceuticals, is $0.0665 per EA (NDC 00904700504), effective Sep 30, 2026.
How has the price of PREGABALIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PREGABALIN 300 MG CAPSULE has declined 70.4%. It has been tracked across 367 weekly CMS publications since Sep 25, 2019.
What are the highest and lowest recorded NADAC prices for PREGABALIN 300 MG CAPSULE?
Since Sep 25, 2019, the NADAC for PREGABALIN 300 MG CAPSULE has ranged from a low of $0.0628 (Nov 20, 2024) to a high of $0.2260 (Nov 13, 2019), with a median of $0.1006 per EA.
Are there cheaper alternatives to PREGABALIN 300 MG CAPSULE?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PREGABALIN 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures PREGABALIN 300 MG CAPSULE?
PREGABALIN 300 MG CAPSULE (NDC 00904700504) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.